bioihbjkbjnl/mcl2 huggingface dataset:
The Effect of Exercise Training and Arch Supported Insoles on Balance and Vertical Jump Performance in Football Players With Foot Pronation Deformity
Condition: Foot; Pronation, Congenital
MeSH terms: Congenital Abnormalities
Study type: Interventional

Summary: 
      This study aims to investigate the effects of foot pronation exercises and arch support
      insoles on balance and vertical jump test in football players.
    

Detailed description: 
      The study took place in FootBalance Turkey, which works on foot analysis and insoles.

      30 professional football players with pronation who divided into two groups. The football
      players in the Experimental Group used insoles and also participated the foot core exercise
      program twice a week for 4 weeks duration. The football players in the Control Group just
      used the insoles.We used the FootBalance assessmnet system for insoles. Navicular Drop Test,
      Y Balance Test, Flamingo Testand Vertical Jump Test applied to evalute foot pronation,
      dynamic balance, static balance and jump performace respectively.
    

Intervention name(s): Using Insoles; Foot Core Exercises
Intervention type(s): Other; Other
Intervention description(s): FootBalance %100 Control Orthopedic insoles used for 4 weeks.; 4 weeks including
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: Foot pronation; Insoles; Footcore exercises
Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC
Condition: Nasopharyngeal Carcinoma
MeSH terms: Carcinoma; Nasopharyngeal Carcinoma
Study type: Observational

Summary: 
      PET/CT and EBV DNA are important in diagnosis of NPC. We consider that combining
      post-treament PET/CT and plasma EBV DNA may be effective in evaluating the hazard of
      progression in the follow-up of Locally Advanced Nasopharyngeal Carcinoma. Hence we establish
      this prospective cohort study.
    

Detailed description: 
      Newly-diagnosed patients with stage III or IV non-metastatic Nasopharyngeal Carcinoma (AJCC
      7th) will be recruited. All subjects receiving chemoradiotherapy will undergo a baseline
      integrated [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed
      tomography (PET/CT) scan or traditional follow-up examination and plasma EBV DNA test before
      the start of chemoradiotherapy.

      Patients receiving IMRT treatment will receive a dedicated FDG PET/CT protocol 12 weeks after
      the end of chemoradiotherapy (primary endpoint).Plasma EBV DNA test will be performed 4, 12,
      24 weeks after the end of IMRT treatment. In patients with negative PET/CT results, 2
      follow-up visits are required to complement nasopharyngoscope examination and plasma EBV DNA
      test in the frist year. All patients will undergo annual PET/CT or traditional follow-up
      examination and plasma EBV DNA test 1 year after completing chemoradiation unless
      recurrent/residual disease is histopathologically-confirmed.

      Patients with a PET/CT result suspecting for residual/recurrent/metastatic tumor must have
      pathological and/or clinical evidence of tumor existence before salvage therapy is started.
    

Intervention name(s): PET/CT and EBV DNA
Intervention type(s): Device
Intervention description(s): PET/CT and EBV DNA will be proformed after the IMRT treatment
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        NPC patients after induction chemotherapy and concurrent chemoradiotherapy or concurrent
        chemoradiotherapy alone
      
Keywords: PET/CT; EBV DNA; predicting predicting
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
Condition: Lymphoma
MeSH terms: Lymphoma; Lymphoma, Non-Hodgkin
Study type: Interventional
Phase: Phase 2

Summary: 
      Phase II trial to compare the effectiveness of interleukin-12 following chemotherapy in
      treating patients who have refractory HIV-associated non-Hodgkin's lymphoma. Drugs used in
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
      die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by
      stimulating a person' white blood cells to kill cancer cells.
    

Detailed description: 
      OBJECTIVES:

      I. Determine the efficacy of interleukin-12 (IL-12) by evaluating its effect on remission
      duration after response to second line chemotherapy with ifosfamide and etoposide in patients
      with HIV-associated non-Hodgkin's lymphoma.

      II. Determine the safety of IL-12 when administered as maintenance therapy in these patients.

      III. Evaluate overall survival of this patient population. IV. Evaluate serum and tissue
      cytokine levels in these patients. V. Evaluate the effect of IL-12 on HIV viral load and on
      functional T-cell assays in these patients.

      VI. Evaluate the effect of IL-12 on Epstein-Barr Virus (EBV) viral load in these patients.

      OUTLINE: This is an open label study.

      All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2
      hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13.
      Courses are repeated every 21 days. Patients who have complete or partial remission after a
      minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12
      SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6
      months or until disease progression. All patients also receive combination antiretroviral
      therapy during study.

      Patients are followed every month for one year, then every 2 months thereafter.
    

Intervention name(s): filgrastim; recombinant interleukin-12; etoposide; ifosfamide
Intervention type(s): Biological; Biological; Drug; Drug
Intervention MeSH terms: Etoposide; Ifosfamide; Interleukin-12
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: AIDS-related peripheral/systemic lymphoma; AIDS-related diffuse large cell lymphoma; AIDS-related immunoblastic large cell lymphoma; AIDS-related small noncleaved cell lymphoma
Aromatherapy for Stress and Burnout Among Healthcare Providers
Condition: Stress; Burnout, Professional; Stress, Job
MeSH terms: Occupational Stress; Burnout, Professional; Burnout, Psychological
Study type: Interventional

Summary: 
      The purpose of this study is to evaluate the potential for inhalation of plant-based aromas
      to reduce stress and burnout among healthcare professionals and staff in hospitals and urgent
      care centers.
    

Detailed description: 
      After being informed about the study and potential risks/benefits, participants will provide
      e-sign informed consent documents and be randomized to one of three groups in a 1:1:1 ratio.
      Each participant will apply the assigned study oil to the jawline for inhalation three times
      daily for a total of 7 days.
    

Intervention name(s): Herbaceous Essential Oil Blend; Citrus Essential Oil Blend; Inert Oil
Intervention type(s): Other; Other; Other
Intervention description(s): Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.; Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.; Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary purpose: Supportive Care
Keywords: aromatherapy; essential oils
Anti-MAG First Administration to Human
Condition: Cerebrovascular Accident
MeSH terms: Stroke
Study type: Interventional
Phase: Phase 1

Summary: 
      GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a
      protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through
      this activity it is hypothesised that it will enhance recovery from neuronal degeneration
      following acute axonal injury, which occurs in spinal cord injury or stroke.
    


Intervention name(s): GSK249320A; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.; Sodium chloride intravenous infusion will be given as matching placebo.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: first time in human,; MAG; monoclonal antibody,; healthy subjects,; GSK249320,
Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.
Condition: Low Back Pain
MeSH terms: Back Pain; Low Back Pain
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this trial is to evaluate the safety and efficacy of once daily orally
      administered GRT6005 in a total of 3 fixed doses compared to placebo in subjects with
      moderate to severe chronic Low Back Pain (LBP). The study includes a maximum of 21 days
      screening period followed by a 2-week titration period and 12-week maintenance double-blind
      treatment period and a 10-14 day safety follow up period. Patients who are eligible for the
      double-blind treatment period will be randomized to one of the following treatment groups:
      GRT6005 low-dose, GRT6005 medium dose, GRT6005 high-dose, Tapentadol or placebo.
    


Intervention name(s): Matching Placebo; Low Dose GRT6005; Medium Dose GRT6005; High Dose GRT6005; Tapentadol
Intervention type(s): Drug; Drug; Drug; Drug; Drug
Intervention MeSH terms: Tapentadol
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Patient Performed Examination for Patients With Intra-articular Hip Pain
Condition: Hip Pain Chronic; Hip Disease
Study type: Interventional

Summary: 
      The primary objective of this study is evaluate the diagnostic accuracy of a patient
      self-administered clinical examination of the hip compared with a traditional clinical
      examination (i.e. index test).
    


Intervention name(s): Patient Self-Administered Diagnostic Exam; Clinician-Performed Diagnostic Exam
Intervention type(s): Other; Other
Intervention description(s): Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.; A clinician-performed diagnostic exam will be completed on the patients.
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Retrospective Study of the Results of Cooled Radiofrequency for Genicular Nerves Neurotomy in 40 Consecutive Patients With Osteoarthritis of the Knee and Painful Knee Arthroplasty
Condition: Osteoarthritis, Knee
MeSH terms: Osteoarthritis; Osteoarthritis, Knee
Study type: Observational

Summary: 
      Analyze the results of cooled radiofrequency in patients with chronic knee pain after one
      year of follow- up.
    

Detailed description: 
      The investigators performed a retrospective case-series reviewed of 40 patients who underwent
      cooled RF of genicular nerves. The investigators evaluated results of the survey of quality
      of life (SF36), knee society score (KSS) and the Visual Analogue Scale (VAS).
    

Intervention name(s): cooled radiofrequency ablation of genicular nerves
Intervention type(s): Procedure
Intervention description(s): Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
Observational model: Case-Only
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        The procedure was performed to 33 patients with OA (two of them with inflammatory causes)
        and in 7 patients with TKA (four with revised TKA).
      
Keywords: Cooled radiofrequency; chronic knee pain; knee arthroplasty; genicular nerve
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
Condition: Urinary Incontinence; Overactive Bladder
MeSH terms: Urinary Incontinence; Urinary Bladder, Overactive
Study type: Interventional
Phase: Phase 2

Summary: 
      This study is designed to investigate whether a new drug may offer safe and effective
      treatment for patients with overactive bladder.
    


Intervention name(s): MK0594
Intervention type(s): Drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
Condition: Alzheimer Disease (AD)
MeSH terms: Alzheimer Disease
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to evaluate the safety and efficacy of a study drug that targets
      an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
    


Intervention name(s): Zagotenemab; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Administered IV; Administered IV
Other intervention name(s): LY3303560
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Memory problems; Cognitive impairment; PERISCOPE-ALZ; Dementia; Tauopathy; Neurofibrillary tangles
A Study of Continuous Blood Pressure Monitoring in Healthy Participants
Condition: Healthy
Study type: Interventional

Summary: 
      The main purpose of this study in healthy participants is to find out whether the traditional
      ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch
      device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes
      in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The
      study will last about 29 days excluding the screening period of 28 days.
    


Intervention name(s): Propranolol; Pseudoephedrine; ABPM and Wearable Novel Devices; No Intervention
Intervention type(s): Drug; Drug; Device; Other
Intervention description(s): Administered orally.; Administered orally.; ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.; No intervention during this period (Control Period)
Intervention MeSH terms: Propranolol; Pseudoephedrine; Ephedrine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Efficacy Study of Two Treatments in the Remission of Vasculitis
Condition: Wegener Granulomatosis; Microscopic Polyangiitis
MeSH terms: Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Vasculitis; Systemic Vasculitis
Study type: Interventional
Phase: Phase 3

Summary: 
      Study of the efficacy of rituximab for maintenance treatment in systemic ANCA-associated
      vasculitis: prospective, multicenter, controlled, randomized comparative study of rituximab
      versus azathioprine
    

Detailed description: 
      Randomized, controlled, national, multicenter, prospective study to compare between
      azathioprine (conventional therapy) and rituximab in patients with systemic ANCA-associated
      vasculitis, in remission (achieved with an induction treatment combining corticosteroids and
      an immunosuppressant, mainly intravenous pulses of cyclophosphamide, and plasma exchanges
      and/or polyvalent immunoglobulins when indicated) after the first flare of the disease (new
      diagnosis) or after a relapse. It is planned to stratify patients by first flare (66% of the
      patients) or relapse (33% of the patients). Patients complying with the inclusion criteria
      may be included when they are in remission from their vasculitis. Patients who have already
      received biologics (antiCD20, antiTNFα) will not be included. Patients will be included at
      the time of remission and then randomized. They will receive maintenance treatment by
      azathioprine for 18 months or a rituximab infusion every 6 months until month 18 (i.e. a
      total of 4 infusions), at the dose of 375 mg/m2 (maximum dosage, 500 mg). ANCA status and
      CD19+ lymphocyte count will be monitored but will not be used to adjust therapy. After the 18
      month length of maintenance phase, i.e. after stopping immunosuppressive maintenance therapy,
      patients will be followed for an additional 10 month period. Patients with Wegener's
      granulomatosis will be prescribed cotrimoxazole 160/800 tid (for 2 additional years).
    

Intervention name(s): Rituximab; Azathioprine
Intervention type(s): Drug; Drug
Intervention description(s): rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.
All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.; azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.
All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
Intervention MeSH terms: Rituximab; Azathioprine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Wegener's granulomatosis,; microscopic polyangiitis,; ANCA-associated vasculitis,; rituximab,; azathioprine
A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo
Condition: Scar Improvement
Study type: Interventional
Phase: Phase 1

Summary: 
      RN1006 has been developed as a stabilized formulation of avotermin which, when dosed once in
      pre-clinical studies in animals, has shown comparable scar improvement efficacy to the
      standard twice-dosed Juvista formulation. The aim of this trial is to investigate the
      efficacy of RN1006 compared to Juvista in a human volunteer model
    


Intervention name(s): Juvista (Avotermin); RN1006 (Avotermin); RN1006 (Avotermin); RN1006 (Avotermin); Juvista (Avotermin); Juvista (Avotermin); Juvista (Avotermin); RN1006 (Avotermin); Placebo
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): 250 ng, twice, intradermal injection, standard formulation; 250 ng, intradermal injection, twice; 205 ng, Intradermal injection, once; 500ng, intradermal injection, once; 250 ng, intradermal injection, twice; 500 ng, intradermal injection, once; 500 ng, intradermal injection, once; 500 ng, intradermal injection, twice; Placebo
Other intervention name(s): juvista; RN1001; RN1006; RN1006; RN1006; Juvista; RN1001; Juvista; RN1001; Juvista; RN1001; RN1006
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
Keywords: Healthy volunteers; Comparison of two formulations; Improvement of scar appearance
Fast Titration Of Quetiapine Versus Currently Approved Titration
Condition: Psychotic Disorders
MeSH terms: Psychotic Disorders
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to evaluate the safety and tolerability of a more rapid dose
      titration in acute schizophrenic patients compared to the conventional titration.
    


Intervention name(s): Quetiapine
Intervention type(s): Drug
Intervention MeSH terms: Quetiapine Fumarate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Schizophrenia; Schizoaffective disorder
Impact of M22 Synergistic Sequential Treatment (SST)
Condition: Improvement of Wrinkles/Elastosis and/or Pigmentation
Study type: Interventional

Summary: 
      Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of
      3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their
      facial skin appearance.

      Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation
      by at least 1 on the FES scale or ≥50% in category scale at 3 months follow-ups in at least
      50% of the study population.
    


Intervention name(s): M22 IPL and ResurFX
Intervention type(s): Device
Intervention description(s): The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
Condition: Hematological Malignancies
MeSH terms: Neoplasms; Hematologic Neoplasms
Study type: Interventional
Phase: Phase 1

Summary: 
      Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part
      2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for
      hematological malignancies
    


Intervention name(s): Study Part 1: KRP203; Study Part 2: KRP203 lower dose; Study Part 2: KRP203 higher dose
Intervention type(s): Drug; Drug; Drug
Intervention description(s): All subjects will receive KRP203 for 111 days
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Computerized Cognitive Bias Intervention for Intolerance of Uncertainty
Condition: Intolerance of Uncertainty; Anxiety
Study type: Interventional

Summary: 
      This investigation examines the efficacy of a brief, one-session computerized interpretation
      bias modification paradigm (CBM-I) in the reduction of intolerance of uncertainty.
      Intolerance of uncertainty is a risk factor for the development and maintenance of various
      forms of psychopathology.
    


Intervention name(s): Active IU CBM-I; Control CBM-I
Intervention type(s): Behavioral; Behavioral
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Prevention
Keywords: Intolerance of uncertainty; Anxiety